Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Its given either by injection into a muscle or under the skin
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
However, in Be(2)-C cells, it reduced ATP content by more than half ( Figure 3D ) without increasing cell death ( Figure 4A ), indicating a cytostatic rather than cytotoxic effect
Sterile and safe, great product
US$ 29.38
US$ 27.05
US$ 25.46
US$ 29.44
US$ 21.96
US$ 25.37
US$ 24.98
